Skip to main content

Eli Lilly and Company (LLY) Stock

Eli Lilly and Company Stock Details, Movements and Public Alerts

Eli Lilly Stock: The GLP-1 Gold Rush Leader

Eli Lilly has become the largest pharmaceutical company at $814 billion market cap, with GLP-1 drugs driving 45% revenue growth. The company expects $60-62 billion in 2025 revenue as Mounjaro and Zepbound dominate diabetes and obesity markets.

52-Week Range

$1,111.99 - $621.50

-4.49% from high · +70.89% from low

Avg Daily Volume

3,589,079

20-day average

100-day avg: 4,391,146

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

49.49

Above market average

Forward P/E

32.26

Earnings expected to grow

PEG Ratio

0.96

Potentially undervalued

Price to Book

38.65

EV/EBITDA

39.23

EPS (TTM)

$20.76

Price to Sales

15.50

Beta

0.37

Less volatile than market

How is LLY valued relative to its earnings and growth?
Eli Lilly and Company trades at a P/E ratio of 49.49, which is above the market average of approximately 20. This premium valuation suggests investors expect above-average growth or the company has competitive advantages justifying the higher multiple. Looking ahead, the forward P/E of 32.26 is lower than the current P/E, indicating analysts expect earnings to grow over the next year. The PEG ratio of 0.96 suggests the stock may be undervalued relative to its growth rate.
What is LLY's risk profile compared to the market?
With a beta of 0.37, Eli Lilly and Company is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 38.65 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

31.00%

Operating Margin

48.30%

EBITDA

$28.73B

Return on Equity

96.50%

Return on Assets

17.60%

Revenue Growth (YoY)

53.90%

Earnings Growth (YoY)

480.40%

How profitable and efficient is LLY's business model?
Eli Lilly and Company achieves a profit margin of 31.00%, meaning it retains $31.00 from every $100 in revenue after all expenses. This is an impressive margin, indicating strong pricing power and efficient cost management that allows the company to generate substantial profits. The operating margin of 48.30% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at 96.50% and ROA at 17.60%, the company generates strong returns on invested capital.
What are LLY's recent growth trends?
Eli Lilly and Company's revenue grew by 53.90% year-over-year, representing robust expansion that significantly outpaces typical market growth rates. This strong top-line performance suggests the company is successfully capturing market share or benefiting from favorable industry trends. Earnings increased by 480.40% year-over-year, outpacing revenue growth through improved margins. These growth metrics should be evaluated against DRUG MANUFACTURERS - GENERAL industry averages for proper context.

Dividend Information

Dividend Per Share

$5.80

Dividend Yield

0.57%

Ex-Dividend Date

Feb 13, 2026

Dividend Date

Dec 10, 2025

What dividend income can investors expect from LLY?
Eli Lilly and Company offers a dividend yield of 0.57%, paying $5.80 per share annually. This modest yield below 2% suggests the company prioritizes growth investments over current income. While the dividend provides some return, investors are likely attracted more by capital appreciation potential than income generation. To receive the next dividend, shares must be purchased before the ex-dividend date of Feb 13, 2026.
How reliable is LLY's dividend for long-term investors?
The dividend sustainability can be assessed through the payout ratio - Eli Lilly and Company pays $5.80 per share in dividends against earnings of $20.76 per share, resulting in a payout ratio of 27.94%. This conservative payout below 30% indicates excellent dividend safety with substantial room for future increases. The company retains most earnings for growth while still rewarding shareholders. The next dividend payment is scheduled for Dec 10, 2025.

Company Size & Market

Market Cap

$921.1B

Revenue (TTM)

$59.42B

Revenue/Share (TTM)

$66.15

Shares Outstanding

895.02M

Book Value/Share

$26.56

Asset Type

Common Stock

What is LLY's market capitalization and position?
Eli Lilly and Company has a market capitalization of $921.1B, classifying it as a mega-cap stock (over $200B). These are the largest, most established companies globally, typically offering stability and liquidity but with more modest growth potential. Mega-caps often pay dividends and weather economic downturns better than smaller companies. With 895.02M shares outstanding, the company's ownership is relatively concentrated. As a major player in the DRUG MANUFACTURERS - GENERAL industry, it competes with other firms in this sector.
How does LLY's price compare to its book value?
Eli Lilly and Company's book value per share is $26.56, while the current stock price is $1,062.10, resulting in a price-to-book (P/B) ratio of 39.99. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As a common stock, this represents equity ownership with voting rights.

Analyst Ratings

Analyst Target Price

$1,075.74

1.28% upside potential

Analyst Recommendations

Strong Buy

4

Buy

17

Hold

8

Sell

0

Strong Sell

1

How reliable are analyst predictions for LLY?
30 analysts cover LLY with 70% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The mixed views reflect uncertainty about the outlook. The consensus target of $1,075.74 implies 1.3% upside, but targets are often adjusted to follow price moves rather than predict them.
What is the Wall Street consensus on LLY?
Current analyst recommendations:4 Strong Buy, 17 Buy, 8 Hold, 01 Strong Sell. The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Dec 14, 2025, 02:10 AM

Technical Indicators

RSI (14-day)

64.25

Neutral

50-Day Moving Average

$938.27

13.20% above MA-50

200-Day Moving Average

$812.89

30.66% above MA-200

MACD Line

21.19

MACD Signal

29.88

MACD Histogram

-8.68

Bearish

What does LLY's RSI value tell investors?
The RSI (Relative Strength Index) for LLY is currently 64.25, indicating the stock is showing bullish momentum (60-70 range). The stock has positive momentum without being extremely overbought. This zone often occurs during healthy uptrends where buyers remain in control. Combined with the price being above the 50-day moving average, this confirms bullish conditions.
How should traders interpret LLY's MACD and moving average crossovers?
MACD analysis shows the MACD line at 21.19 below the signal line at 29.88, with histogram at -8.68. This bearish crossover indicates downward pressure. The wide histogram confirms strong momentum. The 50-day MA ($938.27) is above the 200-day MA ($812.89), forming a golden cross pattern that typically signals a long-term uptrend. Price is currently above both MAs, confirming strength.

Indicators last updated: Dec 16, 2025, 12:52 AM

Active Alerts

Alert Condition
Price decreases by
Threshold
5%
Created
Dec 15, 2025, 03:42 PM
Alert Condition
Forward P/E falls below
Threshold
27.42 x
Created
Dec 15, 2025, 03:42 PM
Alert Condition
Price decreases by
Threshold
5%
Created
Nov 12, 2025, 11:27 PM

Eli Lilly (LLY) Stock Analysis 2025 - Weight Loss Drug Investment Guide

Why Eli Lilly? Understanding the Investment Story

The Obesity Revolution

Eli Lilly stands at the epicenter of the greatest pharmaceutical gold rush since statins, with GLP-1 drugs addressing the global obesity epidemic affecting 1 billion people. Mounjaro generated $5.2 billion in Q2 revenue, up 68% year-over-year, while Zepbound delivered $3.38 billion, up 172%. Combined, these drugs will likely become the best-selling medicines in history by their third year on market.

The market opportunity defies comprehension. Analysts project the GLP-1 market reaching $150 billion annually by early 2030s, larger than the entire pharmaceutical industries of most countries. Lilly dominance stems from tirzepatide dual mechanism providing superior weight loss to competitors. While Novo Nordisk Ozempic grabbed headlines, Lilly drugs deliver better results with potentially fewer side effects.

The Oral Advantage

Orforglipron, Lilly oral GLP-1, achieved 12.4% weight loss in Phase 3 trials - a game-changer for the 90% of patients who avoid injections. As the first oral GLP-1 without food restrictions, orforglipron could capture $50 billion of the market by 2030. Lilly is three years ahead of competitors in oral development, with regulatory submission expected by year-end. Manufacturing advantages mean oral pills can scale without the injection pen constraints limiting current supply.

Valuation: Growth at a Reasonable Price

Despite the massive run-up, Lilly trades at 25.4 times forward earnings with a PEG ratio of 0.3 - suggesting significant undervaluation relative to growth. The company raised 2025 guidance to $60-62 billion in revenue with $21.75-23 in adjusted EPS, representing 30%+ growth. For a company revolutionizing chronic disease treatment, the valuation appears reasonable considering the total addressable market expansion ahead.

Opportunities for 2025 and Beyond

Manufacturing Moat

Lilly massive manufacturing investments create an underappreciated moat. While competitors struggle with supply, Lilly expanded capacity positions it to capture market share through availability alone. The company operational excellence in scaling complex biologics and pivoting to oral production demonstrates execution excellence. In pharmaceuticals, the best drug that patients cannot access loses to available alternatives.

Beyond Weight Loss

GLP-1 drugs show promise treating sleep apnea, cardiovascular disease, kidney disease, and even addiction. Each new indication expands the addressable market by hundreds of millions of patients. Lilly pipeline includes next-generation triple agonists potentially doubling weight loss efficacy. The company transformed from a diabetes specialist to the leader in metabolic disease, a market measured in trillions over coming decades.

Who Is This Stock For?

Perfect For

  • ✓Growth investors seeking pharmaceutical exposure
  • ✓Healthcare bulls believing in GLP-1 revolution
  • ✓Long-term holders comfortable with volatility
  • ✓Thematic investors focused on obesity epidemic

Less Suitable For

  • ✗Value investors concerned about valuation
  • ✗Risk-averse investors worried about competition
  • ✗Short-term traders (high volatility)
  • ✗Dividend-focused investors (low yield)

Investment Recommendation

Conclusion

Eli Lilly represents a generational investment opportunity as GLP-1 drugs reshape global healthcare. The combination of market leadership, oral drug advantage, manufacturing scale, and pipeline depth creates multiple competitive moats. While valuation has expanded, the PEG ratio suggests growth more than justifies the premium. The biggest risk is not competition but execution - can Lilly manufacture enough to meet insatiable demand? With management raising guidance repeatedly, execution appears excellent.
2025 Price Target
$1000-1100
Upside Potential
+22-35%
Risk Level
Moderate-High
Recommendation
Buy on pullbacks < $800

Stay Ahead of the Market with Eli Lilly and Company Alerts

Set up price alerts for Eli Lilly and Company and get notified instantly when the price hits your target. Never miss an important price movement again.